Cadrenal Therapeutics, Inc. — Form 8-K
Filed July 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Item 5.02 indicates a departure of a director or officer and changes to compensatory arrangements, but the 8-K filing text provided does not contain the specific details—no names, titles, effective dates, severance amounts, or new compensation terms are disclosed in the excerpt. The full filing documents are referenced but their content is not reproduced here.
Why this rating
Officer/director changes are routine at small biotech firms. Without disclosed severance or specific roles, magnitude cannot be assessed relative to $24.9M market cap. Likely administrative disclosure.
Extracted items
- 5.02 exec change
- 9.01 exhibits
See more from July 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.